Medtronic’s Amplify Spine Product Not Approvable, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
Medtronic received a non-approvable letter from FDA for its Amplify rhBMP-2 Matrix spinal treatment, the company disclosed in a March 9 regulatory filing.
You may also be interested in...
Medicare Panel Gives Wish List For Bone Morphogenetic Protein Research
Cross-industry cooperation may be needed to develop more effective bone morphogenetic proteins to promote bone growth and fusion, according to a Medicare advisory panel
Panel Narrowly Recommends Medtronic Spine Treatment After Tough Scrutiny
An FDA advisory panel cast a mixed vote on July 27 in support of Medtronic's Amplify rhBMP-2 Matrix spinal treatment, reflecting disagreement about safety and the reliability of some clinical data
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.